Agents targeting the B-cell receptor (BCR) signaling cascade and B-cell lymphoma-2 (BCL2) expand treatment options for high-risk CLL including TP53-disrupted and relapsed/refractory (R/R) disease. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.